SANOFI CONS HEALTHC IND L Net Assets
SANOFI CONS HEALTHC IND L net assets. Based on the latest financial reports, SANOFI CONS HEALTHC IND L (SANOFICONR) has net assets worth Rs3.84 Billion INR (≈ $41.53 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs5.47 Billion ≈ $59.16 Million USD) and total liabilities (Rs1.63 Billion ≈ $17.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is SANOFI CONS HEALTHC IND L growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs3.84 Billion |
| % of Total Assets | 70.2% |
| Annual Growth Rate | 35.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.58 |
Net Assets of SANOFI CONS HEALTHC IND L (2023–2025)
Net assets of SANOFI CONS HEALTHC IND L from 2023 to 2025. This chart illustrates how SANOFI CONS HEALTHC IND L's net assets have evolved over time, based on quarterly financial data. See SANOFI CONS HEALTHC IND L (SANOFICONR) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for SANOFI CONS HEALTHC IND L (2023–2025)
The table below shows the annual net assets of SANOFI CONS HEALTHC IND L from 2023 to 2025. For live market cap and overall valuation, see SANOFI CONS HEALTHC IND L market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Rs3.84 Billion ≈ $41.53 Million |
+40.66% |
| 2024-12-31 | Rs2.73 Billion ≈ $29.52 Million |
+31.50% |
| 2023-12-31 | Rs2.08 Billion ≈ $22.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SANOFI CONS HEALTHC IND L's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
SANOFI CONS HEALTHC IND L Net Assets Breakdown (December 2025)
SANOFI CONS HEALTHC IND L net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs230.00 Million | 5.99% |
| Other Components | Rs3.61 Billion | 94.01% |
| Total Equity | Rs3.84 Billion | 100.00% |
SANOFI CONS HEALTHC IND L Competitors by Market Cap
The table below lists competitors of SANOFI CONS HEALTHC IND L ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
$851.89 Million |
|
CGN Nuclear Technology Development Co Ltd
SHE:000881
|
$852.21 Million |
|
Beijing Hualu Baina Film TV
SHE:300291
|
$853.16 Million |
|
Beijing eGOVA
SHE:300075
|
$853.47 Million |
|
Fujian Boss Software Development Co Ltd
SHE:300525
|
$851.26 Million |
|
Artis Real Estate Investment Trust
TO:AX-UN
|
$851.22 Million |
|
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
|
$851.12 Million |
|
Netac Tech
SHE:300042
|
$851.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SANOFI CONS HEALTHC IND L's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,730,000,000 to 3,840,000,000, a change of 1,110,000,000 (40.7%).
- Net income of 2,401,000,000 contributed positively to equity growth.
- Dividend payments of 1,267,000,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs2.40 Billion | +62.53% |
| Dividends Paid | Rs1.27 Billion | -32.99% |
| Other Changes | Rs-24.00 Million | -0.62% |
| Total Change | Rs- | 40.66% |
Book Value vs Market Value Analysis
This analysis compares SANOFI CONS HEALTHC IND L's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 20.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.94x to 20.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | Rs90.14 | Rs3420.20 | x |
| 2024-12-31 | Rs118.54 | Rs3420.20 | x |
| 2025-12-31 | Rs166.76 | Rs3420.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SANOFI CONS HEALTHC IND L utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 62.53%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 27.33%
- • Asset Turnover: 1.61x
- • Equity Multiplier: 1.42x
- Recent ROE (62.53%) is below the historical average (69.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 79.43% | 30.30% | 1.58x | 1.66x | Rs1.44 Billion |
| 2024 | 66.30% | 24.98% | 1.68x | 1.58x | Rs1.54 Billion |
| 2025 | 62.53% | 27.33% | 1.61x | 1.42x | Rs2.02 Billion |
Industry Comparison
This section compares SANOFI CONS HEALTHC IND L's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $7,618,629,371
- Average return on equity (ROE) among peers: 20.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SANOFI CONS HEALTHC IND L (SANOFICONR) | Rs3.84 Billion | 79.43% | 0.42x | $851.86 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $18.21 Billion | 5.12% | 0.72x | $4.63 Billion |
| NGL Fine-Chem Limited (NGLFINE) | $585.12 Million | 24.34% | 0.73x | $189.24 Million |
| Pfizer Limited (PFIZER) | $6.50 Billion | 52.33% | 0.34x | $1.91 Billion |
| Sanofi India Limited (SANOFI) | $9.32 Billion | 16.89% | 0.29x | $817.71 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $454.99 Million | 18.53% | 1.88x | $578.24 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $10.65 Billion | 7.67% | 0.20x | $139.92 Million |
About SANOFI CONS HEALTHC IND L
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was in… Read more